FDA grants approval for 300mg Plavix
The FDA has approved a supplemental new drug application for a 300 mg tablet of the antiplatelet Plavix from pharmaceutical companies Sanofi-aventis and Bristol-Myers Squibb.

According to the Bridgewater, Mass.-based Bristol-Myers Squibb and the Princeton, N.J.-based Sanofi-aventis, Plavix will facilitate the use of the FDA-approved loading dose for appropriate acute coronary syndrome (ACS) patients as soon as possible after hospital admission.